Skip to main content
Erschienen in:

04.01.2020 | Original Article

Mortality of Chinese patients with polymyositis and dermatomyositis

verfasst von: Xinlei Yang, Yanjie Hao, Xiaohui Zhang, Yan Geng, Lanlan Ji, Guangtao Li, Zhuoli Zhang

Erschienen in: Clinical Rheumatology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the mortality and the causes of death in Chinese patients with polymyositis (PM) and dermatomyositis (DM).

Methods

The clinical data of all consecutive adult PM/DM patients in Rheumatology and clinical immunology department of Peking University First Hospital from January 2007 to Apr2016 were collected. The primary causes of death were identified, the standardized mortality ratio (SMR) and years of life lost (YLL) were calculated based on the National Bureau of Statistics of China for the general population, the survival in the first decade was performed using Kaplan-Meier analysis, and the predictors of mortality were evaluated by multivariable cox regression.

Results

A total of 85 PM and226 DM cases were included and 68 patients died. Infection (52.3%) was the leading cause of death. The overall age and sex adjusted SMR was 6.0(95%CI 3.5–8.5) for PM, and 9.0(95%CI 6.8–11.2) for DM. The YLL of women and men were 12.2 and 18.3 years respectively for PM, and 37.5 and 28.4 years respectively for DM. The 10-year survival of patients with ILD, malignancy or infection was significantly worse than those without, respectively. The independent predictors of mortality for PM/DM patients were age at disease onset, malignancy and infection.

Conclusions

Mortality of PM/DM patients in China is substantial, especially in females, and those with ILD, malignancy or infection. Infection was the leading cause of death. Patients with older age at onset, infection, ILD, and malignancy need to be paid more attention.
Key Points
This is the first comprehensive report about the mortality situation with a large population in PM/DM patients in China including SMR, YLL, and cause of death, Kaplan-Meier survival analysis and Cox regression analysis for mortality risk factors.
The specific SMRs for PM/DM patients with malignancy and interstitial lung disease were also reported in this study. To our knowledge, only two studies worldwide reported SMRs in PM/DM patients and no figure about YLL was reported so far.
Overall, the mortality figures in this study were higher than those from the western countries, and the leading cause of death was different from the western countries.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Oakley P, Benveniste O, Danieli MG, Danko K, Thuy NTP, Vazquez-del Mercado M, Andersson H, de Paepe B, deBleecker J, Maurer B, McCann L, Pipitone N, McHugh N, Betteridge ZE, New P, Cooper RG, Ollier WE, Lamb JA, Krogh NS, Lundberg IE, Chinoy H, all EuroMyositis contributors (2018) The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis 77(1):30–39PubMedCrossRef Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Oakley P, Benveniste O, Danieli MG, Danko K, Thuy NTP, Vazquez-del Mercado M, Andersson H, de Paepe B, deBleecker J, Maurer B, McCann L, Pipitone N, McHugh N, Betteridge ZE, New P, Cooper RG, Ollier WE, Lamb JA, Krogh NS, Lundberg IE, Chinoy H, all EuroMyositis contributors (2018) The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis 77(1):30–39PubMedCrossRef
3.
Zurück zum Zitat Dobloug GC, Svensson J, Lundberg IE, Holmqvist M (2018) Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis 77(1):40–47PubMedCrossRef Dobloug GC, Svensson J, Lundberg IE, Holmqvist M (2018) Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis 77(1):40–47PubMedCrossRef
4.
Zurück zum Zitat Marie I (2012) Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 14:275–285PubMedCrossRef Marie I (2012) Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 14:275–285PubMedCrossRef
5.
Zurück zum Zitat Nuno-Nuno L, Joven BE, Carreira PE, Maldonado-Romero V, Larena-Grijalba C, Cubas IL et al (2017) Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. Rheumatol Int 37(11):1853–1861PubMedCrossRef Nuno-Nuno L, Joven BE, Carreira PE, Maldonado-Romero V, Larena-Grijalba C, Cubas IL et al (2017) Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. Rheumatol Int 37(11):1853–1861PubMedCrossRef
6.
Zurück zum Zitat Mustafa KN, Dahbour SS (2010) Clinical characteristics and outcomes ofpatients with idiopathic inflammatory myopathies from Jordan 1996–2009. Clin Rheumatol 29:1381–1385PubMedCrossRef Mustafa KN, Dahbour SS (2010) Clinical characteristics and outcomes ofpatients with idiopathic inflammatory myopathies from Jordan 1996–2009. Clin Rheumatol 29:1381–1385PubMedCrossRef
7.
Zurück zum Zitat Yu KH, Wu YJ, Kuo CF, See LC, Shen YM, Chang HC, Luo SF, Ho HH, Chen IJ (2011) Survival analysis of patients withdermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol 30:1595–1601PubMedCrossRef Yu KH, Wu YJ, Kuo CF, See LC, Shen YM, Chang HC, Luo SF, Ho HH, Chen IJ (2011) Survival analysis of patients withdermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol 30:1595–1601PubMedCrossRef
8.
Zurück zum Zitat Schiopu E, Phillips K, Macdonald PM, Crofford LJ, Somers EC (2012) Predictors ofsurvival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate, and azathioprine. Arthritis Res Ther 14:R22PubMedPubMedCentralCrossRef Schiopu E, Phillips K, Macdonald PM, Crofford LJ, Somers EC (2012) Predictors ofsurvival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate, and azathioprine. Arthritis Res Ther 14:R22PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Yamasaki Y, Yamada H, Ohkubo M, Yamasaki M, Azuma K, Ogawa H, Mizushima M, Ozaki S (2011) Longterm survivaland associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis:experience in a single institute in Japan. J Rheumatol 38:1636–1643PubMedCrossRef Yamasaki Y, Yamada H, Ohkubo M, Yamasaki M, Azuma K, Ogawa H, Mizushima M, Ozaki S (2011) Longterm survivaland associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis:experience in a single institute in Japan. J Rheumatol 38:1636–1643PubMedCrossRef
10.
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347PubMedCrossRef Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347PubMedCrossRef
11.
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407PubMedCrossRef Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407PubMedCrossRef
12.
Zurück zum Zitat Sontheimer RD (2002) Would a new name hasten the acceptanceof amyopathic dermatomyositis (dermatomyositissine´ myositis) as a distinctive subset within the idiopathicinflammatorydermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46:626–636PubMedCrossRef Sontheimer RD (2002) Would a new name hasten the acceptanceof amyopathic dermatomyositis (dermatomyositissine´ myositis) as a distinctive subset within the idiopathicinflammatorydermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46:626–636PubMedCrossRef
13.
14.
Zurück zum Zitat American Thoracic Society, European Respiratory Society (2002) American Thoracic Society/European RespiratorySociety international multidisciplinary consensus classificationof the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277–304CrossRef American Thoracic Society, European Respiratory Society (2002) American Thoracic Society/European RespiratorySociety international multidisciplinary consensus classificationof the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277–304CrossRef
15.
Zurück zum Zitat Sato S, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Tamura M et al (2018) Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology 57:1212–1221 Sato S, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Tamura M et al (2018) Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology 57:1212–1221
16.
Zurück zum Zitat Schwartz T, Diederichsen LP, Lundberg IE et al (2016) Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies. RMD Open 2:e000291PubMedPubMedCentralCrossRef Schwartz T, Diederichsen LP, Lundberg IE et al (2016) Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies. RMD Open 2:e000291PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Gosselink R, Kovacs L, Decramer M (1999) Respiratory muscle involvement in multiple sclerosis. Eur Respir J 13:449–454PubMedCrossRef Gosselink R, Kovacs L, Decramer M (1999) Respiratory muscle involvement in multiple sclerosis. Eur Respir J 13:449–454PubMedCrossRef
18.
Zurück zum Zitat Lee PP, Lee TL, Ho MH, Wong WH, Lau YL (2007) Recurrent major infections injuvenile-onset systemic lupus erythematosus–a close linkwith long-term disease damage. Rheumatology 46:1290–1296PubMedCrossRef Lee PP, Lee TL, Ho MH, Wong WH, Lau YL (2007) Recurrent major infections injuvenile-onset systemic lupus erythematosus–a close linkwith long-term disease damage. Rheumatology 46:1290–1296PubMedCrossRef
19.
Zurück zum Zitat Andersen PK, Borgan O, Gill RD, Keiding N (1993) Statistical models based on counting processes. Springer-Verlag, New York, p 322CrossRef Andersen PK, Borgan O, Gill RD, Keiding N (1993) Statistical models based on counting processes. Springer-Verlag, New York, p 322CrossRef
20.
Zurück zum Zitat Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF (2011) Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 63:1182–1189PubMedCrossRef Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF (2011) Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 63:1182–1189PubMedCrossRef
21.
Zurück zum Zitat Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C et al (2017) Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheum 69:1067–1077CrossRef Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C et al (2017) Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheum 69:1067–1077CrossRef
22.
Zurück zum Zitat Chiang CL (1968) The life table and its construction. In: Introduction to stochastic processes in Bioststatistics. John Wiley & Sons, New York, pp 189–214 Chiang CL (1968) The life table and its construction. In: Introduction to stochastic processes in Bioststatistics. John Wiley & Sons, New York, pp 189–214
23.
Zurück zum Zitat Newell C (1994) Methods and Models in Demography. John Wiley & Sons, Chichester(UK), pp 63–81 Newell C (1994) Methods and Models in Demography. John Wiley & Sons, Chichester(UK), pp 63–81
24.
Zurück zum Zitat Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ, Luo SF (2011) Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 165:1273–1279PubMedCrossRef Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ, Luo SF (2011) Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 165:1273–1279PubMedCrossRef
25.
Zurück zum Zitat Chen IJ, JanWu YJ, Lin CW, Fan KW, Luo SF, Ho HH et al (2009) Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 28:639–646PubMedCrossRef Chen IJ, JanWu YJ, Lin CW, Fan KW, Luo SF, Ho HH et al (2009) Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 28:639–646PubMedCrossRef
26.
Zurück zum Zitat Obert J, Freynet O, Nunes H, Brillet PY, Miyara M, Dhote R, Valeyre D, Naccache JM (2016) Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease. Rheumatol Int 36(12):1727–1735PubMedCrossRef Obert J, Freynet O, Nunes H, Brillet PY, Miyara M, Dhote R, Valeyre D, Naccache JM (2016) Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease. Rheumatol Int 36(12):1727–1735PubMedCrossRef
27.
Zurück zum Zitat Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132PubMedCrossRef Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132PubMedCrossRef
28.
Zurück zum Zitat Wu C, Wang Q, He L, Yang E, Zeng X (2018) Hospitalization mortality and associated risk factors in patients with polymyositis and dermatomyositis: a retrospective case-control study. PLoS One 13(2):e0192491PubMedPubMedCentralCrossRef Wu C, Wang Q, He L, Yang E, Zeng X (2018) Hospitalization mortality and associated risk factors in patients with polymyositis and dermatomyositis: a retrospective case-control study. PLoS One 13(2):e0192491PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Marie I, Menard JF, Hachulla E, Cherin P, Benveniste O, Tiev K et al (2011) Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum 41:48–60PubMedCrossRef Marie I, Menard JF, Hachulla E, Cherin P, Benveniste O, Tiev K et al (2011) Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum 41:48–60PubMedCrossRef
30.
Zurück zum Zitat Chen IJ, Tsai WP, Wu YJ, Luo SF, Ho HH, Liou LB et al (2010) Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology 49:2429–2437PubMedCrossRef Chen IJ, Tsai WP, Wu YJ, Luo SF, Ho HH, Liou LB et al (2010) Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology 49:2429–2437PubMedCrossRef
31.
Zurück zum Zitat Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC (2012) Predictors of survival in a cohort ofpatients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 14:R22PubMedPubMedCentralCrossRef Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC (2012) Predictors of survival in a cohort ofpatients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 14:R22PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Marie I, Hachulla E, Chérin P, Hellot MF, Herson S, Levesque H et al (2005) Opportunistic infectionsin polymyositis and dermatomyositis. Arthritis Rheum 53:155–165PubMedCrossRef Marie I, Hachulla E, Chérin P, Hellot MF, Herson S, Levesque H et al (2005) Opportunistic infectionsin polymyositis and dermatomyositis. Arthritis Rheum 53:155–165PubMedCrossRef
33.
Zurück zum Zitat Gordon PA, Winer JB, Hoogendijk JE et al (2012) Immunosuppressant andimmunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 8:CD003643 Gordon PA, Winer JB, Hoogendijk JE et al (2012) Immunosuppressant andimmunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 8:CD003643
34.
Zurück zum Zitat Vermaak E, Tansley SL, McHugh NJ (2015) The evidence for immunotherapy indermatomyositis and polymyositis: a systematic review. Clin Rheumatol 34:2089–2095PubMedCrossRef Vermaak E, Tansley SL, McHugh NJ (2015) The evidence for immunotherapy indermatomyositis and polymyositis: a systematic review. Clin Rheumatol 34:2089–2095PubMedCrossRef
35.
Zurück zum Zitat Redondo-Benito C, Villar-Gomez, Trallero-Araguas, Fernández-Codina, Pinal-Fernandez, Rodrigo-Pendás J, Selva-O'Callaghan (2018) Opportunistic infections in patients with idiopathic inflammatory myopathies. Int J Rheum Dis 21(2):487–496PubMedCrossRef Redondo-Benito C, Villar-Gomez, Trallero-Araguas, Fernández-Codina, Pinal-Fernandez, Rodrigo-Pendás J, Selva-O'Callaghan (2018) Opportunistic infections in patients with idiopathic inflammatory myopathies. Int J Rheum Dis 21(2):487–496PubMedCrossRef
36.
Zurück zum Zitat Brandt D, Gershwin ME (2006) Common variable immunedeficiency and autoimmunity. Autoimmun Rev 5:465–470PubMedCrossRef Brandt D, Gershwin ME (2006) Common variable immunedeficiency and autoimmunity. Autoimmun Rev 5:465–470PubMedCrossRef
37.
Zurück zum Zitat Tha-In T, Bayry J, Metselaar HJ et al (2008) Modulation of thecellular immune system by intravenousimmunoglobulin. Trends Immunol 29:608–615PubMedCrossRef Tha-In T, Bayry J, Metselaar HJ et al (2008) Modulation of thecellular immune system by intravenousimmunoglobulin. Trends Immunol 29:608–615PubMedCrossRef
38.
Zurück zum Zitat Kaveri SV, Lacroix-Desmazes S, Bayry J (2008) The antiinflammatory IgG. N Engl J Med 359:307–309PubMedCrossRef Kaveri SV, Lacroix-Desmazes S, Bayry J (2008) The antiinflammatory IgG. N Engl J Med 359:307–309PubMedCrossRef
39.
Zurück zum Zitat Jordan SC, Toyoda M, Vo AA (2009) Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 88:1–6PubMedCrossRef Jordan SC, Toyoda M, Vo AA (2009) Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 88:1–6PubMedCrossRef
40.
Zurück zum Zitat Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M et al (2017) 2017 European league against rheumatism/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheum 69(12):2271–2282CrossRef Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M et al (2017) 2017 European league against rheumatism/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheum 69(12):2271–2282CrossRef
Metadaten
Titel
Mortality of Chinese patients with polymyositis and dermatomyositis
verfasst von
Xinlei Yang
Yanjie Hao
Xiaohui Zhang
Yan Geng
Lanlan Ji
Guangtao Li
Zhuoli Zhang
Publikationsdatum
04.01.2020
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 5/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04910-w

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Mit Lidocain kommt der Darm nicht schneller in Schwung

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

Koronare Herzkrankheit: Das waren die Top-Studien in 2024

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Inhalative Steroide bei COPD nicht kardioprotektiv

  • 10.01.2025
  • COPD
  • Nachrichten

Ob inhalative Kortikosteroide (ICS) COPD-Kranke außer vor akuten Exazerbationen auch vor kardiovaskulären Komplikationen schützen können, ist unklar. Eine bevölkerungsbasierte Studie aus England spricht nicht dafür.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.